<p>Alto Neuroscience, Inc. (NYSE:ANRO - 获取免费报告) 被六家目前对该公司进行覆盖的评级公司给予&#34;买入&#34;的平均评级，Marketbeat Ratings 报告称。六位分析师对该股票给出了买入建议。过去一年更新股票覆盖的经纪公司中，平均 12 个月目标价格为 35.00 美元。</p>
<p>获取 <strong>Alto Neuroscience</strong> 警报：</p>
<p>一些分析师最近对 ANRO 股票发表了评论。William Blair 在 6 月 12 日星期三的报告中重申了对 Alto Neuroscience 股票的&#34;表现优异&#34;评级。Rodman &amp; Renshaw 在 6 月 21 日星期五的报告中开始对 Alto Neuroscience 进行覆盖。他们为该公司设定了&#34;买入&#34;评级和 43.00 美元的目标价格。</p>
<p>查看我们对 Alto Neuroscience 的最新分析</p>
<h2>Alto Neuroscience 股价下跌 8.0%</h2>
<p>NYSE ANRO 的股价于周五开盘为 8.37 美元。Alto Neuroscience 过去一年的最低价为 8.15 美元，最高价为 24.00 美元。该公司的流动比率为 26.02，速动比率为 26.02，负债权益比为 0.05。该公司的五十日移动平均价格为 12.07 美元。</p>
<p>Alto Neuroscience (NYSE:ANRO - 获取免费报告) 上次发布季度财报是在 5 月 14 日星期二。该公司报告该季度每股亏损 0.76 美元，低于市场预期的 0.46 美元。股票研究分析师预计 Alto Neuroscience 今年将发布-2.93 美元的每股收益。</p>
<h2>内部人员活动</h2>
<p>在其他 Alto Neuroscience 新闻中，内部人员亚当·萨维茨（Adam Savitz）于 7 月 9 日星期二的交易中购买了该公司的 12,069 股股票。这些股票的平均价格为 12.60 美元，总价值为 152,069.40 美元。购买完成后，该内部人员现在在公司拥有 36,920 股股票，价值约 465,192 美元。该购买交易已在提交给美国证券交易委员会的文件中披露，可以通过此超链接访问。</p>
<h2>Alto Neuroscience 的机构交易</h2>
<p>对冲基金和其他机构投资者最近对该公司的持股进行了调整。Rhumbline Advisers 在第二季度期间收购了 Alto Neuroscience 的新股份，价值约 113,000 美元。Federated Hermes Inc. 在第二季度将其在 Alto Neuroscience 的持仓增加了 33.3%。Federated Hermes Inc. 现在拥有该公司的 12,000 股股票，价值 128,000 美元，比之前多购买了 3,000 股。纽约梅隆银行在第二季度收购了 Alto Neuroscience 的新股份，价值约 252,000 美元。德克萨斯大学 AM 投资管理公司在第一季度收购了 Alto Neuroscience 的新股份，价值约 340,000 美元。最后，Bowie Capital Management LLC 在第二季度收购了 Alto Neuroscience 的新股份，价值约 462,000 美元。</p>
<h2>关于 Alto Neuroscience（获取免费报告</h2>
<p>Alto Neuroscience, Inc. 在美国作为一家处于临床阶段的生物制药公司运营。其产品管线包括 ALTO-100，目前正在用于治疗重性抑郁症（MDD）患者的 2b 期临床试验；以及正在用于治疗创伤后应激障碍的 2a 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们比 Alto Neuroscience 更喜欢的股票</li>
<li>3 家 2021 年前景良好的金融科技公司</li>
<li>大麻行业：盈利能力成为焦点</li>
<li>医疗保健股票解析：为什么您可能想要投资</li>
<li>亚马逊股价暴跌：是时候买入了吗？</li>
<li>消费者自由支配股票解析</li>
<li>在 e.l.f. Beauty 中买入低点：分析师指向新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的财务数据生成的，以便为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 卡玛拉·哈里斯的觉醒政治可能导致股价暴跌 50%（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTIz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTIz"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Alto Neuroscience 股票？</h2>
<p>在考虑购买 Alto Neuroscience 股票之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票... 而 Alto Neuroscience 不在这个列表上。</p>
<p>虽然分析师目前对 Alto Neuroscience 给出&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ANRO

<p>Alto Neuroscience, Inc. (NYSE:ANRO) 收到了六位分析师的平均 “买入” 评级。该股票的 12 个月目标价为$35.00。内部交易活动包括一位内部人士购买了 12,069 股该股票。该公司是一家临床阶段生物制药公司</p>

<p>Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been given an average rating of &#34;Buy&#34; by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.</p>
<div class="lb-trans"><p>Alto Neuroscience, Inc. (NYSE:ANRO - 获取免费报告) 被六家目前对该公司进行覆盖的评级公司给予&#34;买入&#34;的平均评级，Marketbeat Ratings 报告称。六位分析师对该股票给出了买入建议。过去一年更新股票覆盖的经纪公司中，平均 12 个月目标价格为 35.00 美元。</p>
</div><p>Get <strong>Alto Neuroscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Alto Neuroscience</strong> 警报：</p>
</div><p>A number of analysts recently commented on ANRO shares. William Blair reiterated an &#34;outperform&#34; rating on shares of Alto Neuroscience in a report on Wednesday, June 12th. Rodman &amp; Renshaw initiated coverage on Alto Neuroscience in a report on Friday, June 21st. They set a &#34;buy&#34; rating and a $43.00 target price for the company.</p>
<div class="lb-trans"><p>一些分析师最近对 ANRO 股票发表了评论。William Blair 在 6 月 12 日星期三的报告中重申了对 Alto Neuroscience 股票的&#34;表现优异&#34;评级。Rodman &amp; Renshaw 在 6 月 21 日星期五的报告中开始对 Alto Neuroscience 进行覆盖。他们为该公司设定了&#34;买入&#34;评级和 43.00 美元的目标价格。</p>
</div><p><strong>View Our Latest Analysis on Alto Neuroscience</strong></p>
<div class="lb-trans"><p>查看我们对 Alto Neuroscience 的最新分析</p>
</div><h2>Alto Neuroscience Stock Down 8.0 %</h2>
<div class="lb-trans"><h2>Alto Neuroscience 股价下跌 8.0%</h2>
</div><p>Shares of NYSE ANRO opened at $8.37 on Friday. Alto Neuroscience has a one year low of $8.15 and a one year high of $24.00. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $12.07.</p>
<div class="lb-trans"><p>NYSE ANRO 的股价于周五开盘为 8.37 美元。Alto Neuroscience 过去一年的最低价为 8.15 美元，最高价为 24.00 美元。该公司的流动比率为 26.02，速动比率为 26.02，负债权益比为 0.05。该公司的五十日移动平均价格为 12.07 美元。</p>
</div><p>Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.30). Equities research analysts expect that Alto Neuroscience will post -2.93 EPS for the current year.</p>
<div class="lb-trans"><p>Alto Neuroscience (NYSE:ANRO - 获取免费报告) 上次发布季度财报是在 5 月 14 日星期二。该公司报告该季度每股亏损 0.76 美元，低于市场预期的 0.46 美元。股票研究分析师预计 Alto Neuroscience 今年将发布-2.93 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人员活动</h2>
</div><p>In other Alto Neuroscience news, insider Adam Savitz bought 12,069 shares of the business's stock in a transaction dated Tuesday, July 9th. The shares were purchased at an average price of $12.60 per share, with a total value of $152,069.40. Following the completion of the purchase, the insider now owns 36,920 shares in the company, valued at approximately $465,192. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.</p>
<div class="lb-trans"><p>在其他 Alto Neuroscience 新闻中，内部人员亚当·萨维茨（Adam Savitz）于 7 月 9 日星期二的交易中购买了该公司的 12,069 股股票。这些股票的平均价格为 12.60 美元，总价值为 152,069.40 美元。购买完成后，该内部人员现在在公司拥有 36,920 股股票，价值约 465,192 美元。该购买交易已在提交给美国证券交易委员会的文件中披露，可以通过此超链接访问。</p>
</div><h2>Institutional Trading of Alto Neuroscience</h2>
<div class="lb-trans"><h2>Alto Neuroscience 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $113,000. Federated Hermes Inc. grew its position in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $128,000 after purchasing an additional 3,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $252,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $340,000. Finally, Bowie Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at about $462,000.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持股进行了调整。Rhumbline Advisers 在第二季度期间收购了 Alto Neuroscience 的新股份，价值约 113,000 美元。Federated Hermes Inc. 在第二季度将其在 Alto Neuroscience 的持仓增加了 33.3%。Federated Hermes Inc. 现在拥有该公司的 12,000 股股票，价值 128,000 美元，比之前多购买了 3,000 股。纽约梅隆银行在第二季度收购了 Alto Neuroscience 的新股份，价值约 252,000 美元。德克萨斯大学 AM 投资管理公司在第一季度收购了 Alto Neuroscience 的新股份，价值约 340,000 美元。最后，Bowie Capital Management LLC 在第二季度收购了 Alto Neuroscience 的新股份，价值约 462,000 美元。</p>
</div><h2>About Alto Neuroscience (Get Free Report</h2>
<div class="lb-trans"><h2>关于 Alto Neuroscience（获取免费报告</h2>
</div><p>Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.</p>
<div class="lb-trans"><p>Alto Neuroscience, Inc. 在美国作为一家处于临床阶段的生物制药公司运营。其产品管线包括 ALTO-100，目前正在用于治疗重性抑郁症（MDD）患者的 2b 期临床试验；以及正在用于治疗创伤后应激障碍的 2a 期临床试验。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Alto Neuroscience</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>The Cannabis Sector: Profitability Takes Center Stage</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Buy the Dip in e.l.f. Beauty: Analysts Point to a New High</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>五只我们比 Alto Neuroscience 更喜欢的股票</li>
<li>3 家 2021 年前景良好的金融科技公司</li>
<li>大麻行业：盈利能力成为焦点</li>
<li>医疗保健股票解析：为什么您可能想要投资</li>
<li>亚马逊股价暴跌：是时候买入了吗？</li>
<li>消费者自由支配股票解析</li>
<li>在 e.l.f. Beauty 中买入低点：分析师指向新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=ANRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的财务数据生成的，以便为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Kamala Harris’ Woke Politics Could Lead to 50% Stock Collapse (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 卡玛拉·哈里斯的觉醒政治可能导致股价暴跌 50%（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTIz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9123&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Alto Neuroscience right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Alto Neuroscience 股票？</h2>
</div><p>Before you consider Alto Neuroscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Alto Neuroscience 股票之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票... 而 Alto Neuroscience 不在这个列表上。</p>
</div><p>While Alto Neuroscience currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然分析师目前对 Alto Neuroscience 给出&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Alto Neuroscience, Inc.（纽约证券交易所代码：ANRO）获得分析师的平均评级为 “买入”